

Dr Warren Hyer  
Consultant Paediatric Gastroenterologist

Probiotics – a cure for all?

No conflict of interest to declare

# Aims

---

- ▶ To change your opinion of probiotic use in children
- ▶ To base your decision on high quality evidence and not studies prejudiced by publication bias
- ▶ Have an understanding on the number needed to treat
- ▶ Consider other strategies in preference

# Outcomes – this is our knowledge so far

---

## In favour of probiotics

- ✓ Prevention and treating viral gastroenteritis
- ✓ Preventing antibiotic associated diarrhoea



## Uncertain benefit

- ? Preventing NEC
- ? Treat H pylori
- ? Treatment for IBS
- ? Treatment for ulcerative colitis
- ? Treatment for infantile colic
- ? Preventing atopy

## Not proven

- ✗ Treatment of Crohns disease
- ✗ Prevention or treatment for human cancers

# Topics we will cover





## Bottom line

These are the slides worth remembering

# So what are we talking about

---

Proper probiotics

Not a drinking yoghurt



Lactobacilli  
Bifidobacterium  
Streptococcus

# Good versus bad

---

## Good bugs


- ▶ *Lactobacillus rhamnosus*
- ▶ *Bifidobacterium lactis*
- ▶ *Streptococcus thermophilus*
  
- ▶ *Faecalibacterium prausnitzii* – less abundant in IBD

## Bad bugs

- ▶ *Klebsiella*
- ▶ *Pseudomonas*
- ▶ *Serratia*
- ▶ *Proteus*

# Role of microbiota in GI disease in children – increasing interest

---





# The first opportunity for getting the environment right

---





## Bottom Line

Mode of delivery

Neonatal antibiotics

Prematurity

Delays intestinal commensal  
probiotic bacterial  
colonisation compared to  
vaginal delivery





St. Mark's Hospital  
and Academic Institute

# The Bottom Line

So lets look at the data?

# Prevention of nosocomial diarrhoea




Weizman et al Pediatrics 2005



## Safety and Efficacy of an Attenuated Vaccine against Severe Rotavirus Gastroenteritis

Guillermo M Ruiz-Palacios, Irene Pérez-Schael, F Raúl Velázquez, Hector Abate, et al. Boston: Jan2006 Vol. 354,

Iss. 1; pg. 11, 14 pgs



**Figure 1. Cumulative Hazard of a First Episode of Severe Gastroenteritis.**

The cumulative hazard of a first episode was estimated as a minus-log transformation (of log data to nonlog data) of the Kaplan–Meier survival curve during the period from dose 1 until one year of age among all the infants who received at least one dose of either vaccine or placebo. The difference between receiving placebo and receiving vaccine was significant ( $P < 0.001$  by the log-rank test).



▶ After meta analysis:



**Number needed to treat**

7 children would need to have been given LGG to prevent 1 child from developing rotavirus gastroenteritis


**NNT = 7**

The rotavirus vaccine is superior

# Treatment of diarrhoea

## Allen et al Probiotics for treating infectious diarrhoea. Cochrane 2010

Review: Probiotics for treating acute infectious diarrhoea  
 Comparison: 1 Primary diarrhoea outcomes  
 Outcome: 3 Mean stool frequency on day 2



- ▶ But by how much do they improve the episode
- ▶ ONE DAY
- ▶ And does that prevent hospital admission



Not worth it


Strain  
dependent

Have to be  
given early


Only help in  
healthy children



# Antibiotic associated diarrhoea



## ► Metaanalysis- Goldenburg 2015 Cochrane




**NNT = 10**



# Preventing C difficile infection post anti biotics

## % C difficile related diarrhoea post antibiotic



- ▶ Probiotics reduce risk of C difficile associated diarrhoea post antibiotics by 64%

Goldenberg  
Cochrane database 2013

- ▶ Antibiotic use worldwide is rising
- ▶ Antibiotic resistance escalates
- ▶ Vaccination regimes prevent sepsis
- ▶ Probiotics are effective in reducing risk of *Clostridium difficile*



**Just give less antibiotics**

Better education about fever

Complete vaccination schedules

Avoid PPI's

Wash hands

Use less broad spectrum antibiotic

# Necrotising enterocolitis

---

## Summary of data

- ▶ 24 RCT
- ▶ Probiotic group vs placebo had reduced risk of NEC (n=5520). RR 0.43
- ▶ Probiotic group reduced mortality (n=5112)  
RR 0.65
- ▶ Sepsis rate identical
- ▶ Reduced time to feeding



AlFaleh Probiotics for prevention of NEC  
Cochrane 2014

# So they work?

---

▶ So probiotics confer benefit:

1. Reduce mortality
2. Reduce morbidity

- ▶ What is the optimal probiotic formulation?
- ▶ We do not know about the safety and efficacy of probiotics in VLBW?
- ▶ What is the duration?
- ▶ In formula or human milk
- ▶ Studies do not have the same end point?

Studies on individual strains are still promising: (Review JPEN 2015)

- ▶ L reuteri:
- ▶ Reduced time to full feeds (by 1.34 days)
- ▶ Risk of late onset sepsis (RR 0.66)
- ▶ Duration of hospitalisation by 11 days



For NEC

**I concede**, the data supports use of probiotics as a prevention strategy.


- ▶ Studies on individual strains are still promising: (review JPEN 2015)
- ▶ L reuteri:
- ▶ Reduced time to full feeds (by 1.34 days)
- ▶ Risk of late onset
- ▶ Duration

For NEC

**I concede**, the data supports use of

**Number needed to prevent one case of NEC is between 21 and 27**

But why not have more effective ways of preventing NEC?




# Treatment of H pylori

---

- ▶ Probiotics – increased eradication rate OR 1.95
  - ▶ But does not get eradication up to 90%
- ▶ Probiotics reduced risk of side effects RR 0.32
- ▶ Maastricht consensus Gut 2012:
  - ▶ “certain probiotics show promising results as adjuvant treatment in reducing side effects”





## **H pylori**



May improve eradication rate

May improve risk of side effects

But does it matter?


Does it improve compliance?

# Prevention of atopic disease



# Cochrane conclusion

Review: Probiotics in infants for prevention of allergic disease and food hypersensitivity  
 Comparison: 1 Probiotic versus no probiotic - all infants  
 Outcome: 1 All allergic disease



- ▶ Instead of use probiotics, why not strive for a vaginal delivery and breast feed?



## Insufficient

“There is insufficient evidence to recommend the addition of probiotics to infant feeds for prevention of allergic disease or food hypersensitivity. Although there was a reduction in clinical eczema in infants, this effect was not consistent between studies”

- ▶ **European Academy of Allergy and Clinical Immunology (EAACI) 2014**
  - ▶ There is no evidence to support use of probiotics for food allergy prevention
  
- ▶ **World Allergy Organisation 2015 (WAO)**
  - ▶ Significant benefit of probiotic supplement in reducing the risk of eczema when used in the last trimester (RR 0.57 if given to mother; RR 0.8 if given to infant).


**Bottom line**

Confused?



# And as for treating atopic disease.....

- ▶ SCORAD eczema score
- ▶ Weston et al 2004 Arch Dis Child



To treat his eczema: that degree of change is hardly going to change his eczema....you would be better off changing his milk




**For treatment:**

**Not proven to be effective**

# Irritable bowel syndrome

response rate abdo pain in children with IBS n=50



Busserman J Ped 2005

## Adult practice

- ▶ Moderate benefit only
- ▶ Variable end points
- ▶ Often mixed with constipation studies

**NNT = 4**



## Irritable bowel syndrome: new and emerging treatments

Magnus Halland, Yuri A Saito



CrossMark

Division of Gastroenterology and  
Hepatology, Mayo Clinic, Rochester,  
MN 55905, USA

Correspondence to: YA Saito  
saito.yuri@mayo.edu

Cite this as: *BMJ* 2015;350:h1622  
doi: 10.1136/bmj.h1622

### ABSTRACT

Irritable bowel syndrome is one of the most common gastrointestinal disorders in developed nations. It is characterized by abdominal pain, altered bowel habits, and bloating. Several non-pharmacological and pharmacological agents, which target

## IBS

There are so many  
better tools for  
managing IBS:

Hypnotherapy


FODMAP reduction

Herbal therapy

Drug therapies

# With the concurrent use of antibiotics and rise in prevalence of IBD and relationship to Westernised medicines

---



- ▶ Lack of biodiversity
- ▶ Cause or effect
- ▶ Linked to Westernised lifestyle
- ▶ Imbalance in normal gut microbiota due to antibiotic use might have sustained effect on GI immune tolerance

## Gut microbiota

ORIGINAL ARTICLE


### Geographical patterns of the standing and active human gut microbiome in health and IBD

Ateequr Rehman,<sup>1</sup> Philipp Rausch,<sup>2,3</sup> Jun Wang,<sup>2,3</sup> Jurgita Skieceviciene,<sup>1,4</sup>

and Academic Institute

# Ulcerative colitis


---



- ▶ 40% of children use alternative therapies
- ▶ There is good reason to consider probiotics might work

# Adult studies are promising especially in pouchitis

Review: Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis  
 Comparison: 7 VLS#3 versus placebo  
 Outcome: 1 Maintenance of clinical remission




## 2.4 Probiotics

### ECCO Statement 6G

*E coli* Nissle is an effective alternative to 5-ASA for maintenance  
 [EL1b, RG A]


# In ulcerative colitis


## Children study



## Adult study

### Maintenance of remission for UC






## For UC

Probiotics cannot be **generally** recommended for ulcerative colitis

But ECCO states there is a role in the adult consensus statement



**Crohn disease**

No role. No evidence


## 3.7 Probiotics

### Statement 21

Probiotics are not recommended for maintenance of remission [EL3 (pediatrics) EL2 (adults)]

# Infantile colic

---



- ▶ Hardly striking
- ▶ n=50
- ▶ Another 3 studies show the same reduced crying times


J Ped 2015



167 breast fed infants

# RESEARCH

## Treating infant colic with the probiotic *Lactobacillus reuteri*: double blind, placebo controlled randomised trial



167 breast fed infants

RESEARCH

Treating infant colic with the probiotic *Lactobacillus reuteri*: double blind, placebo controlled, randomised

Contradictory study, in breast fed, n=589,  
JAMA Paediatric 2014

Reducing crying time by 51 mins per day by 1 month

Placebo    L reuteri


# What about changing mother's diet?

- ▶ Reduction in cry fuss duration by 25%

Iacovou et al Mat Child Health 2012



**% reduction in crying**



How many allergic foods to reduce?  
Vit D and dietician

St. Mark's Hospital  
and Academic Institute



## **Diet change**

Has more value than  
reflux medicines

Don't over restrict  
maternal diet

Change infant formula  
for 2 weeks – then re  
offer regular CMF

## EDITORIALS

---

### Probiotics and infant colic

Still a hammer in search of a nail

So, with such a dearth of good evidence, perhaps the more important question is: “Should we be treating infant colic at all?” A great deal of accumulated clinical experience tells us that children with colic incur no serious long term effects from the disorder, and that symptoms abate with time. The potential harm associated with diagnostic testing and treatment of infants is likely to surpass the harm from colic itself.



## **Probiotics**

Hardly a striking difference

Might reduce crying times

But there are other strategies that may work better – see infantile colic session



# Controversial use of probiotics

---

## Obesity



## Non alcoholic steatohepatitis

ORIGINAL ARTICLE: HEPATOLOGY AND NUTRITION

---

Probiotics to Adolescents With Obesity: Effects on Inflammation and Metabolic Syndrome

Probiotics did not impact on metabolic markers.

EDITORIALS



## Gut Microbiota, the Genome, and Diet in Atherogenesis


Joseph Loscalzo, M.D., Ph.D.

olism. Changes in the microbial population within the gut can lead to alterations in normal metabolism that can potentially promote the development of obesity, the metabolic syndrome, and type 2 diabetes mellitus.<sup>2</sup> Cotter and colleagues<sup>3</sup> have recently defined this interaction between the genome and microbiome as a coordinated “supraorganismal” metabolism (a term



# But I ask Krish

**Do you really believe probiotics can get you from this to this? These are lifestyle choices, not gut flora?**



# Other conditions where there is no evidence probiotics are effective

---

- ▶ Constipation
- ▶ Prevention of extra-intestinal infections in children
- ▶ Cancer prevention

# Bottom lines

---

## ? In favour of probiotics

- ✓ Treating viral gastroenteritis
- ✓ Preventing antibiotic associated diarrhoea

## Uncertain benefit


- ? Preventing NEC
- ? Treat H pylori
- ✗ Treatment for IBS
- ? Treatment for ulcerative colitis
- ✗ Treatment for infantile colic
- ✗ Preventing atopy

## Not proven

- ✗ Treatment of Crohns disease
- ✗ Prevention or treatment for human cancers

# But it's the wrong question

Don't ask do probiotics work -  
But ask if there is a better strategy for  
that illness/ symptom



probiotics

other  
strategies

## Probiotics or con?



Online publication during the past week of two randomised trials of probiotics will intensify debate about their role as nutritional supplements. In the largest study of probiotics to date, the Dutch Acute Pancreatitis Study Group, writing in *The Lancet*, showed that a combination of lactobacilli and bifidobacteria more than doubled mortality compared with placebo in 298 patients with predicted severe acute pancreatitis. By contrast, David Pyne and colleagues report in the *British Journal of Sports Medicine*, that another species of lactobacillus halved the frequency of respiratory infections in 20 high-performance distance runners.

How these findings translate to the 2 million people who consume probiotics regularly in the UK and who are neither world-class athletes, nor have acute pancreatitis is not clear. Though many studies have attributed benefit to probiotics, most have involved specific illnesses in hospital settings. The benefits of different strains and their mechanisms of action in typical consumers are uncertain. Indeed, the validity of advertised health

benefits is being examined by a court in California, USA.

Regulation of the worldwide US\$4 billion probiotic market is disjointed, since substantiation of claims must satisfy different local criteria depending on whether the products are considered foods, supplements, or drugs. Since July, 2007, the European Union requires scientific evidence to support claims of benefit. But labelling is often incomplete and misleading, despite recommendations by the Food and Agriculture Organization in 2002 to specify strain details, number of viable bacteria, storage conditions, and consumer information. For instance, a UK survey in 2006 found that half of 50 probiotics tested did not contain the specified strain or stated concentration.

By raising questions of safety and efficacy, the above trials should generate further probiotic research, which concerned consumers will want extended to community studies. Meanwhile, the WHO definition that probiotics confer a health benefit on the host might need revision, because after the Dutch group's results, it is no longer tenable to regard probiotics as risk-free. ■ *The Lancet*

See [Comment](#) page 634

See [Articles](#) page 651

For the paper by Pyne et al see the *British Journal of Sports Medicine* 2008; published online Feb 13. DOI:10.1136/bjism.2007.044628

## Probiotics or con?



Online publication during the past week of two randomised trials of probiotics will intensify debate about their role as nutritional supplements. In the largest study of probiotics to date, the Dutch Acute

benefits is being examined by a court in California, USA. Regulation of the worldwide US\$4 billion probiotic market is disjointed, since substantiation of claims must satisfy different local criteria depending on whether the

Science Photo Library

Inadequate strain in the assay  
 \$4-8 billion market  
 Storage  
 Survival in the stomach  
 And is it risk free?

ents, or drugs. Requires scientific labelling is often recommendations on in 2002 to bacteria, storage for instance, a UK probiotics tested did concentration. acy, the above research, which

is not clear. Though many studies have attributed benefits to probiotics, most have involved specific illnesses in hospital settings. The benefits of different strains and their mechanisms of action in typical consumers are uncertain. Indeed, the validity of advertised health

concerned consumers will want extended to community studies. Meanwhile, the WHO definition that probiotics confer a health benefit on the host might need revision, because after the Dutch group's results, it is no longer tenable to regard probiotics as risk-free. ■ *The Lancet*

For the paper by Pyne et al see the *British Journal of Sports Medicine* 2008; published online Feb 13. DOI:10.1136/bjism.2007.044628



Page 1 of 2



BMJ 2016;352:i227 doi: 10.1136/bmj.i227 (Published 23 February 2016)

## EDITORIALS



CrossMark  
click for updates

# “Vaginal seeding” of infants born by caesarean section

How should health professionals engage with this increasingly popular but unproved practice?



St. Mark's Hospital  
and Academic Institute

Chelsea and Westminster Hospital   
NHS Foundation Trust



- ▶ 25% of babies born by Caesarean section
- ▶ Modest increase risk in obesity, asthma and autoimmune disease
- ▶ Alteration in microbiota
- ▶ Neonatal antibiotics increase risk of atopy



## Probiotics

We are just trying to reproduce normal gut flora.

Can we avoid changing the flora?

2.4 antibiotic courses before age 2 years in the US

# Faecal transplantation in UC

---



- ▶ Effective in *C. difficile* infection (NICE approved)
- ▶ Use in ulcerative colitis
- ▶ Can be used to maintain UC remission

# For *C. difficile* treatment

The NEW ENGLAND JOURNAL of MEDICINE

REVIEW ARTICLE

Dan L. Longo, M.D., *Editor*


## *Clostridium difficile* Infection

Daniel A. Leffler, M.D., and J. Thomas Lamont, M.D.




St. Mark's Hospital  
and Academic Institute

**A** Rates of Cure




**B** Microbial Diversity



# The irony of westernised living

The New England Journal of Medicine



**Figure 1. Inverse Relation between the Incidence of Prototypical Infectious Diseases (Panel A) and the Incidence of Immune Disorders (Panel B) from 1950 to 2000.**

In Panel A, data concerning infectious diseases are derived from reports of the Centers for Disease Control and Prevention, except for the data on hepatitis A, which are derived from Joussemet et al.<sup>12</sup> In Panel B, data on immune disorders are derived from Swarbrick et al.,<sup>10</sup> Dubois et al.,<sup>13</sup> Tuomilehto et al.,<sup>14</sup> and Pugliatti et al.<sup>15</sup>

## ► Reduction in risk of atopic disease



Bring the cow, and  
filth back into the  
kitchen

Reduce urbanisation

Lancet 2001



## The Bottom Line

# The first opportunity for getting the environment right

---





## Bottom Line

Mode of delivery

Neonatal antibiotics

Prematurity

Delays intestinal  
commensal probiotic  
bacterial colonisation  
compared to vaginal  
delivery



St. Mark's Hospital  
and Academic Institute

# The Bottom Line

# Do the probiotics work

---

## In favour of probiotics

- ✓ Prevention and treating viral gastroenteritis
- ✓ Preventing antibiotic associated diarrhoea

## Uncertain benefit

- ✓ Preventing NEC
- ✓ Treat H pylori
- ? Treatment for IBS
- ✓ Treatment for ulcerative colitis
- ? Treatment for infantile colic
- ? Preventing atopy

## Not proven

- ✗ Treatment of Crohns disease
- ✗ Prevention or treatment for human cancers



# But are they worth giving?

---

## In favour of probiotics

- 👉 Prevention and treating viral gastroenteritis
- 👉 Preventing antibiotic associated diarrhoea

## Uncertain benefit

- 👉 Preventing NEC
- 👉 Treat H pylori
- 👉 Treatment for IBS
- 👉 Treatment for ulcerative colitis
- 👉 Treatment for infantile colic
- 👉 Preventing atopy

## Not proven

- ❌ Treatment of Crohns disease
- ❌ Prevention or treatment for human cancers

👉 = **there is a better way**

# Aims

---

- ▶ To change your opinion of probiotic use in children ✓
- ▶ To base your decision on high quality evidence and not studies prejudiced by publication bias ✓
- ▶ Have an understanding on the number needed to treat ✓
- ▶ Consider other strategies in preference ✓